REMAP-CAP to Partner With Eisai on Innovative Trial to Combat COVID

LOS ANGELES–(BUSINESS WIRE)– #REMAP_CAP–Global Coalition for Adaptive Research (LOS ANGELES, CA) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) — The Global Coalition for Adaptive Research (GCAR), in collaboration with UPMC (University of Pittsburgh Medical Center), and Eisai Co., Ltd. announce today that Eisai Co., Ltd. will join REMAP-COVID, a substudy of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multip